Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement

Completed · Phase 3 · Has a placebo group

Conditions studied: PAIN

In brief

This study involves research. Pregabalin is a Food and Drug Administration (FDA) medication approved in the United States for the treatment of nerve pain related to diabetes and post-herpetic neuralgia "shingles", and for seizures in adults. The purpose of this research is to study the effect of oral Pregabalin on spinal neurotransmitters in subjects undergoing Total Knee Replacement Surgery (TKA). TKA is associated with considerable postoperative pain which if unrelieved may result in prolonged hospital stay, inability to participate in rehabilitation programs, poor outcomes, and greater use of health-care resources. This study examines the effect of pregabalin administered for TKA on pain-related neurotransmitter concentrations.

Key facts

Study ID

NCT00729690

Run by

Asokumar Buvanendran

People needed

48

Starts

2008-08-01

Expected to finish

2011-07-01

Last updated by the study team

2012-12-19

Who can join

Age: 55 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• History of osteoarthritis
• Subjects who can understand and communicate in English

You may not qualify if…

• Younger than 55 years or older than 75 years.
• American Society of Anesthesiologists physical status IV
• Prior use of pregabalin or gabapentin will not be an exclusionary criterion; however patients will have been withdrawn from these medications at least 14 days before surgery
• Patients who are currently enrolled in another investigational study.

Where it is running

• Rush University Medical Center — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.